Navigation Links
Arius announces new findings in Trop-2 and CD59 CANCER antibody programs
Date:10/25/2007

- CD59 antibody uses novel approach to "de-cloak" cancers -

TORONTO, Oct. 25 /PRNewswire-FirstCall/ - ARIUS Research Inc., (TSX: ARI), a biotechnology company discovering and developing the next wave of antibody therapeutics, today announced that new findings have been presented from its Trop-2 and CD59 antibody programs. ARIUS scientists will discuss the Company's Trop-2 and CD59 abstracts at the AACR press conference today at 9:30 a.m. PT.

"Both our Trop-2 and CD59 antibody programs have demonstrated novel approaches in treating cancer. Our Trop-2 antibody is a novel target and has been linked to aggressive cancers in the scientific literature, while our CD59 program has demonstrated the ability to foil a cancer cell's ability to evade the immune system," said Dr. David Young, President and CEO. "These programs, in addition to our CD44 cancer stem cell program, were generated through our proprietary drug discovery technology, FunctionFIRST(TM), which is inherently designed to produce novel antibodies and identify unique cancer targets."

Trop-2 Proffered Paper Presentation

ARIUS' Trop-2 targeting antibody has demonstrated a significant anti-tumor effect in animal models of human pancreatic cancer, inhibiting tumor growth by up to 100 percent. Subsequent testing showed efficacy in animal models of breast, colon and prostate cancers. The antibody compared favorably with Taxotere in prostate cancer model and has also shown the ability to be highly potent at low-dose concentrations.

Additional information can be found at the AACR-NCI-EORTC 2007 International Conference on Molecular Targets and Cancer Therapeutics in San Francisco at the following location and time: AR47A6.4.2, a functional naked monoclonal antibody targeting Trop-2, demonstrates in vivo efficacy in human pancreatic, colon, breast and prostate cancer models. Proffered Paper Session 3, Thursday, October 25, 2007 from 5:15 - 5:30 p.m. in the Third Floor Ballroom a
'/>"/>

SOURCE ARIUS Research Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Streptococcus salivarius
2. Streptococcus salivarius
3. Speaker announces business members of IT Task Force
4. Doyle announces technology tax credits for Berbee
5. Doyle announces new energy, global warming policies
6. Doyle announces $80M renewable energy strategy
7. GE announces first installation of Discovery VCT
8. UWM announces winners of RGI awards
9. Third Wave announces two senior management appointments
10. Mirus announces new method for making antibodies
11. Merge announces sofware updates, upcoming acquisition
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... -- MEI Pharma, Inc. (Nasdaq: MEIP ), an oncology ... cancer, announced today that Daniel P. Gold , Ph.D., ... NewsMakers in the Biotech Industry conference on Friday, September ... Broadway Hotel & Conference Center in New York ... accessed at www.meipharma.com . A replay will be available ...
(Date:9/18/2014)... 18 septembre 2014 Mapi, société créée ... 1974, a été depuis 40 ans l,un ... cliniques traditionnelles par des évaluations recentrées sur ... les impacts économiques des traitements. ... A cours d,une récente conférence téléphonique ...
(Date:9/18/2014)... SeqLL Inc., the owner of ... today the closing of a $1M Series-A funding ... Diagnostic Technologies, will increase the power of tSMS™ ... in March 2013 by Daniel Jones, a former ... BioSciences, SeqLL has continued to offer Helicos’ sequencing ...
(Date:9/18/2014)... sweeteners, promoted as aids to weight loss and diabetes ... and metabolic disease; and they do it in a ... the gut microbiota the substantial population of bacteria ... experiments in mice and humans, were published today in ... Elinav of the Weizmann Institute,s Immunology Department, who led ...
Breaking Biology Technology:MEI Pharma To Present At BioCentury's NewsMakers Conference 2MEI Pharma To Present At BioCentury's NewsMakers Conference 31974 - 2014 - Mapi fête ses 40 ans 2SeqLL Closes Series-A Funding Round for Expansion of Single Molecule Sequencing 2Gut bacteria, artificial sweeteners and glucose intolerance 2Gut bacteria, artificial sweeteners and glucose intolerance 3
... /PRNewswire-FirstCall/ - Angiotech Pharmaceuticals,Inc. (NASDAQ: ANPI , ... company, today announced that it has elected to ... trials for its Vascular Wrap,product candidate in patients ... to evaluate an imbalance of infections that have,been ...
... April 21 A group of German,investors is about to ... for a purchasing price of up to EUR 750,000. The ... will be subscribed,to by the investors. It will become effective ... Sangui account and after the capital increase will,have been entered ...
... an interview with a researcher, please contact the Communications and ... tip. For more information on ORNL and its research and ... If you have a general media-related question or comment, you ... HOMELAND SECURITY -- Protecting ports . . . ...
Cached Biology Technology:Angiotech elects to suspend Vascular Wrap(TM) pivotal clinical trials 2Angiotech elects to suspend Vascular Wrap(TM) pivotal clinical trials 3Angiotech elects to suspend Vascular Wrap(TM) pivotal clinical trials 4Investors Acquire Share in Sangui BioTech GmbH 2Story tips from the Department of Energy's Oak Ridge National Laboratory, March 2008 2Story tips from the Department of Energy's Oak Ridge National Laboratory, March 2008 3
(Date:9/17/2014)... scientists were instrumental in the creation of the Santa ... classify the fire threat potential of the powerful, hot, ... into an inferno. The index was introduced Sept. 17 ... and San Diego Gas and Electric. , The index ... that will be used to help fire agencies and ...
(Date:9/17/2014)... his doctoral student have designed a device based on ... fog and dew., The device could provide water in ... globe., Cheng Luo, professor in the Mechanical & Aerospace ... same College of Engineering department, published "Bioinspired Plate-Based Fog ... Chemical Society) Applied Materials & Interfaces ...
(Date:9/17/2014)... A rare genetic disorder known as Jacobsen syndrome has ... investigation by researchers at San Diego State University and ... suggesting better treatment options for people with Jacobsen syndrome, ... underpinnings of autism., Jacobsen syndrome affects approximately 1 in ... It occurs in a person when there is a ...
Breaking Biology News(10 mins):UCLA scientists play key role in developing new Santa Ana Wildfire Threat Index 2Shorebird's beak inspires UT Arlington research on water collection 2A link between Jacobsen syndrome and autism 2
... new field study confirms that an invasive weed called ... suggesting it will continue to spread across much of ... acres of grazing land almost worthless. The research, ... Research Service, was one of the most comprehensive studies ...
... What: , The 33rd CTRC-AACR San Antonio ... prevention, epidemiological, laboratory, translational and clinical breast cancer research. ... pipeline, new approaches with existing agents and emerging biology ... To help you plan your coverage of the symposium, ...
... growing potatoes, at least for growing seed potatoes. Newco ... together with Neiker-Tecnalia (the Basque Institute for Agricultural Research ... of a novel system known as aeroponics. What ... given that never before in this country the first ...
Cached Biology News:Invading weed threatens devastation to western rangelands 2Invading weed threatens devastation to western rangelands 3Newco produces seed potatoes in the open air 2Newco produces seed potatoes in the open air 3
... The MEGAscript RNAi Kit is ... large mass amounts of ready-to-use ... non-mammalian systems. The MEGAscript RNAi ... patented high-yield transcription technol-ogy and ...
UGT1A6 (D-20)...
... With its patented technology, the Lone Wolf ... any Normally Open proportional valve available on ... operation, provides repeatable high-speed performance, and ensures ... , Enhances system control and patient ...
Normal Hamster Serum...
Biology Products: